Preferences help
enabled [disable] Abstract
Number of results
2015 | 5 | 1 | A11-A15
Article title

Liposomal doxorubicin in first line metastatic HER-2-positive breast cancer for prevention the cardiotoxicity

Title variants
Languages of publication
We describe a 62 year old female with metastatic HER-2-positive breast cancer, and with independent cardiovascular comorbidities. She was earlier treated with J131 therapy due to thyroid toxicity. She developed grade 2 mitral and tricuspid valvular insufficiency as a result of uncontrolled hypertension. In 2013, the patient was diagnosed with luminal B2 breast cancer with liver and bone metastases, and a large infiltration of the left breast together with the surrounding soft tissue. She was treated with liposomal doxorubicin and cyclophosphamide, with the dose of anthracycline slightly reduced to 50 mg/m2 because of the elevated liver enzymes. She was in complete remission during treatment, without any cardiac or hematologic toxicity. The treatment was prolonged to eight cycles until the liver tests returned to normal. The cumulative dose of liposomal doxorubicin amounted to 400 mg/m2 (with the maximum recommended dose of 600 mg/m2). We decided to administer the liposomal form of doxorubicin, which is less cardiotoxic than conventional doxorubicin, as first-line treatment in order to prevent cardiotoxicity in a patient who is a candidate for another cardiotoxic therapy involving trastuzumab in the future. The patient’s disease progressed 10 months following the completion of first-line therapy. There are no cardiologic contraindications to trastuzumab and there are no signs of liposomal doxorubicin-related cardiotoxicity or deterioration of the valvular insufficiency.
Physical description
  • Chair and Clinic of Oncology and Brachytherapy , Faculty of Medicine, Nicolaus Copernicus University, Ludwik Rydygier Collegium Medicum in Bydgoszcz, the Franciszek Lukaszczyk Oncology Centre in Bydgoszcz
  • Szmit S, Szczylik C. Pegylated liposomal doxorubicin and risk of cardiovascular events. Współcz. Onkol. 2009: 13(1): 1-8.
  • Barrett-Lee PJ, Dixon JM, Farrell C et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann of Oncol. Advanced Access 2009; 1-11.
  • Chmielowska E, Kwiatkowski M. Liposomal doxorubicin-induced cardiotoxicity – case report. Onkologia w Praktyce Klinicznej 2011; 7(3): 152-156.
  • Perez EA, Suman VJ, Davidson NE et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaksel with or without trastuzumab in the North Central Cancer Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008; 26(8): 1231-1138.
  • Batist G, Ramakrishnan G, Sekhar Rao Ch et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposom-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444-1454.
  • Bręborowicz E, Bręborowicz P, Litwiniuk M, Tomczak P. Anthracycline-induced cardiomyopathy, an essential diagnostic and therapeutic problem in oncological practice. Współczesna Onkologia 2007; 11(4): 204-209.
  • Szmit S, Głogowska I, Jurczak W. Niepegylowana doksorubicyna liposomalna – zastosowanie w polichemioterapii nowotworów litych i chorób limfoproliferacyjnych. Onkologia w praktyce klinicznej 2013; 4.
  • Harris L, Batist G, Belt R et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomised multicenter trial as a first line therapy of metastatic breast carcinoma Cancer 2002; 94: 25-36.
  • Batist G, Harris L, Azarnia N et al. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anti cancer Drugs 2006; 17(5): 587-595.
  • Stradivari F, Palmieri C. Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer Expert Rev. Anticancer Ther 2008; 8(12): 1859-1869.
  • Goldhirsh A, Wood WC, Coates AS et al. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St Gallen International expert Consensus on the primary therapy of early breast cancer 2011. Ann of Oncol 2011; 22(8): 1736-1747.
  • Szmit S, Kownacki Ł, Torbicki A. Myocardial dysfunction related to trastuzumab therapy – is effective treatment always possible? OncoReview 2014; 4(2): A62-A68.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.